GlassScriptPhysician profile
Edward S Rubin
NPI 1174563431
$47,080.37
in general payments reported to CMS, 2019-2025
56 companies · $8,533 in 2025
The $8,533 reported for 2025 was more than what 95% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,507 · 2021: $2,616 · 2022: $3,850 · 2023: $4,823 · 2024: $13K · 2025: $8,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,000 · Food and Beverage: $5,747 · Travel and Lodging: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,000.00 |
| Food and Beverage | $5,746.84 |
| Travel and Lodging | $683.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $14,088.35 | 2022-2024 | Mild Device Kit |
| Mdd US Operations, LLC | $11,769.44 | 2019-2020 | |
| Boston Scientific Corporation | $10,268.19 | 2019-2025 | Intracept, General - Pain Management, Superion Indirect Decompression System |
| Nevro Corp. | $1,686.74 | 2019-2024 | Senza |
| Relievant Medsystems, INC. | $956.15 | 2021-2023 | Intracept |
| Scilex Pharmaceuticals INC. | $709.41 | 2019-2024 | Ztlido |
| Mml US, INC. | $601.65 | 2022-2025 | Reactiv8 |
| Collegium Pharmaceutical, INC. | $588.03 | 2019-2025 | Belbuca, Xtampza |
| Medtronic, INC. | $516.25 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.87 | 2019-2023 | Relistor |
| Tersera Therapeutics LLC | $383.51 | 2019-2025 | Prialt |
| Redhill Biopharma INC. | $355.83 | 2020-2022 | |
| Biodelivery Sciences International, INC. | $341.71 | 2019-2021 | |
| Forte Bio-Pharma LLC | $337.22 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Virtus Pharmaceuticals LLC | $279.31 | 2020-2024 | Levorphanol Tartrate |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.